Drug Profile


Alternative Names: Integrelin; Integrilin; Intrifiban; SCH 60936

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals
  • Developer GlaxoSmithKline; Merck & Co; Millennium Pharmaceuticals; Schering-Plough
  • Class Ischaemic heart disorder therapies; Peptides
  • Mechanism of Action Fibrinogen receptor antagonists; GPIIb-IIIa antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute coronary syndromes; Myocardial infarction; Unstable angina pectoris
  • Discontinued Stroke

Most Recent Events

  • 17 Jul 2013 Biomarkers information updated
  • 30 Mar 2009 Discontinued - Phase-III for Acute coronary syndromes in World (IV)
  • 15 Oct 2008 Safety and efficacy data from the three-year ASSIST trial in Myocardial infarction released by the University of Ottawa Heart Institute
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top